Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses

Version 1 : Received: 28 September 2022 / Approved: 30 September 2022 / Online: 30 September 2022 (03:22:56 CEST)

A peer-reviewed article of this Preprint also exists.

Haghmorad, D.; Yousefi, B.; Eslami, M.; Rashidy-Pour, A.; Tarahomi, M.; Tavaf, M.J.; Soltanmohammadi, A.; Zargarani, S.; Kamyshnyi, A.; Oksenych, V. Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses. Current Issues in Molecular Biology 2022, 44, 5728–5740, doi:10.3390/cimb44110388. Haghmorad, D.; Yousefi, B.; Eslami, M.; Rashidy-Pour, A.; Tarahomi, M.; Tavaf, M.J.; Soltanmohammadi, A.; Zargarani, S.; Kamyshnyi, A.; Oksenych, V. Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses. Current Issues in Molecular Biology 2022, 44, 5728–5740, doi:10.3390/cimb44110388.

Abstract

Multiple sclerosis (MS) is a demyelinating autoimmune disorder of the central nervous system (CNS). Experimental autoimmune encephalomyelitis (EAE) has been widely used to determine the pathogenesis of the disease and evaluate new treatment strategies for MS. Therefore, we investigated the efficacy of oral administration of a Myelin Oligodendrocyte Glycoprotein (MOG) in the treatment of EAE. Female C57BL/6 mice were utilized in three groups (Control group: received PBS orally; prevention group: oral administration of MOG35-55 two weeks before EAE induction; treatment group: oral administration of MOG35-55 after EAE induction. MOG administration, both as prevention and treatment, significantly controlled clinical score, weight loss, CNS inflammation, and demyelination, mainly through the modulation of T cell proliferation, reduction of pro-inflammatory cytokines and transcription factors, including TNF-α, IFN-γ, IL-17, T-bet, and ROR-γt. MOG administration, both as prevention and treatment, also induced anti-inflammatory cytokines and transcription factors, including IL-4, TGF-β, GATA-3, and Foxp3. The results showed that oral administration of MOG, both as prevention and treatment, could efficiently control EAE development. Immunomodulatory mechanisms include the induction of Th2 and Treg cells and the suppression of pro-inflammatory Th1 and Th17 cells.

Keywords

Multiple Sclerosis; Experimental autoimmune encephalomyelitis; Myelin Oligodendrocyte Glyco-protein; Immunomodulatory mechanisms

Subject

Biology and Life Sciences, Immunology and Microbiology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.